MetabolGut: a rapid assay platform to evaluate the impact drugs on lipid-handlingpathways and chylomicron-associated drug distribution using stem cell-drivenhuman absorptive enterocytes.

MetabolGut：一个快速检测平台，使用干细胞驱动的人体吸收性肠上皮细胞来评估药物对脂质处理途径和乳糜微粒相关药物分布的影响。

• 批准号: 10766493
• 负责人: Bill Thelin
• 金额: $ 34.33万
• 依托单位: ALTIS BIOSYSTEMS, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-01 至 2024-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10766493
• 关键词: 3-Dimensional; Address; Amino Acids; Apical; Applications Grants; Architecture; Biological Assay; Biological Availability; Biosensor; Biotechnology; Blood Circulation; Cell Culture Techniques; Cell Differentiation process; Cell Line; Cells; Chimeric Proteins; Chylomicrons; Collaborations; Colon; Detection; Dietary Fats; Disease; Donor person; Drug Kinetics; Drug Modelings; Drug Screening; Drug Transport; Elements; Enterocytes; Epidemic; Epithelium; Etiology; Excretory function; Exposure to; Fatty Acids; Fatty acid glycerol esters; Flow Cytometry; Foundations; Gene Transfer Techniques; Goals; Health; Hepatic; Human; Hydrogels; Hyperlipidemia; Hypertension; Insulin Resistance; Intestines; Kinetics; Lipids; Lipoproteins; Liver Circulation; Lymphatic System; Metabolic; Metabolic Diseases; Metabolism; Methods; Modality; Modeling; Nonesterified Fatty Acids; North Carolina; Nutrient; Obesity; Occupations; Oral; Organ Donor; Organ Transplantation; Organoids; Pathway interactions; Pharmaceutical Preparations; Phase; Physiological; Physiology; Play; Pre-Clinical Model; Process; Proliferating; Property; Rapid screening; Reader; Reproducibility; Role; Scientist; Small Intestines; System; Technology; Thick; Thin Layer Chromatography; Tissues; Toxicology; Unhealthy Diet; Universities; Validation; Xenobiotics; absorption; cancer cell; cell type; commercialization; detection assay; detection limit; dietary; drug development; drug discovery; drug distribution; drug testing; high throughput screening; improved; in vitro Model; in vivo; innovation; lipophilicity; lymphatic circulation; metabolic engineering; metabolomics; monolayer; novel; novel strategies; nutrient absorption; preclinical efficacy; prototype; rapid detection; rapid test; sedentary; stem cells; sugar

Project Summary Maintaining healthy physiology of the human gut is a large focus of Pharma. Models to study drug/nutrient absorption, xenobiotics, toxicology, and preclinical efficacies are hampered by the lack of accurate, reproducible, and easy to use cell culture models to evaluate such topics. For these reasons, there is a strong need for better in vitro models that recapitulate disease states of the human gut, and better platforms for drug discovery and validation. Lipid-handling is central to human health conditions and pharmacokinetics. Lipid-related metabolic disorders (i.e. obesity, insulin resistance, hyperlipidemia, and hypertension) are a global epidemic and predicted to increase as sedentary jobs and unhealthy diets increase. Treatments for metabolic disorders are sparse with limited efficacy highlighting the need for more broadly effective drugs. Lipid-handling mechanisms by Absorptive Enterocytes (AEs) can strongly influence oral drug Absorption, Distribution, Metabolism and Excretion (ADME), and drug bioavailability can be negatively and positively regulated by AE lipid-handing as many lipid soluble drugs are associated with chylomicrons (CMs). CM-associated-drug export by AEs is a first-line metric of bioavailability for lipophilic drugs with no accurate preclinical model. New tactics that harness lipid- handling mechanisms have strong potential to improve drug engineering for metabolic diseases, bioavailability and efficacy. To meet this need Altis Biosystems Inc., an early-stage biotechnology company, will collaborate with scientists at the University of North Carolina at Chapel Hill to develop Absorptive Enterocytes (AEs) on a high-throughput 96-Traswell format. ‘MetabolGut’ is a monolayer of differentiated AEs derived from the foundational technology, RepliGutTM, which is a stem cell-driven monolayer of human epithelium derived the small intestine or colon of organ donors and contains all of the proliferative and differentiated cell types found in vivo. The goal of this Phase I proposal is to develop four innovative elements: 1) rapid fluorescent readouts for lipid absorption and export, 2) simultaneous rapid detection of barrier integrity and fatty acid export, 3) rapid and highly sensitive identification of fatty acid metabolic species using non-radioisotope methods, 4) rapid fluorescent quantification of chylomicron (CM) export. While elements 1-3 have shown substantial utility for academic studies, they will be explored for commercial viability. Element 4 will be developed de novo as it represents a new assay for high-throughput detection of CM export and CM-associated drug quantification.

项目概要 维持人体肠道的健康生理是制药模型研究的一个重点。 药物/营养吸收、异生物质、毒理学和临床前疗效因缺乏 准确、可重复且易于使用的细胞培养模型来评估此类主题。 强烈需要更好的体外模型来概括人类肠道的疾病状态，并且 更好的药物发现和验证平台对人类健康至关重要。 与脂质相关的代谢紊乱（即肥胖、胰岛素抵抗、 高脂血症和高血压）是一种全球流行病，预计随着久坐工作和 不健康饮食增加。代谢紊乱的治疗方法很少，且疗效有限。 需要更广泛有效的吸收性肠细胞（AE）的脂质处理机制。 可以强烈影响口服药物的吸收、分布、代谢和排泄（ADME）以及药物 AE 脂质处理可以对生物利用度进行负向和正向调节，正如许多脂溶性物质一样 AE 的药物与乳糜微粒 (CM) 相关的药物输出是一线指标。 没有准确的临床前模型的亲脂性药物的生物利用度。 处理机制具有改善代谢疾病药物工程的巨大潜力， 为了满足这一需求，Altis Biosystems Inc. 成立了一家早期生物技术公司。 公司将与北卡罗来纳大学教堂山分校的科学家合作开发 高通量 96-Traswell 格式的吸收性肠细胞 (AE) 是单层的。 源自干细胞驱动的基础技术 RepliGutTM 的差异化 AE 人类上皮单层源自器官捐献者的小肠或结肠，包含所有 该第一阶段提案的目标是体内发现的增殖和分化的细胞类型。 开发四个创新要素：1) 用于脂质吸收和输出的快速荧光读数，2) 同时快速检测屏障完整性和脂肪酸输出，3）快速且高灵敏度 使用非放射性同位素方法鉴定脂肪酸代谢种类，4) 快速荧光 乳糜微粒 (CM) 输出的量化虽然元素 1-3 已显示出巨大的实用性。 学术研究后，将探索 Element 4 的商业可行性。 它代表了一种高通量检测 CM 输出和 CM 相关药物的新方法 量化。